The Latest Cardiac and Vascular News
– Sales of $10.7 billion, including $2.4 billion of COVID-19 diagnostic testing-related sales – Sales growth of 28.7 percent; organic sales growth of 28.4 percent – GAAP diluted EPS from continuing operations growth of 103.4 percent; adjusted diluted EPS growth of 52.6 percent – Delivered more than 300 million COVID-19 […]
– New national reimbursement enables access to transcatheter mitral valve repair procedures with MitraClip for people with secondary mitral regurgitation, significantly expanding the eligible patient population ABBOTT PARK, Ill., Jan. 20, 2021 /PRNewswire/ — Abbott (NYSE: ABT) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) revised its National Coverage Determination (NCD) […]
– Abbott’s HeartMate 3™ heart pump approved for use for pediatric patients battling advanced heart failure – This life-saving technology provides new treatment option for underserved population ABBOTT PARK, Ill., Dec. 17, 2020 /PRNewswire/ — Abbott (NYSE: ABT) today announced the U.S. Food and Drug Administration (FDA) has approved updated labeling for the […]
Virtual reality training improved cath lab staff learning engagement by 45% and knowledge retention by 72% 87% of studies show higher medical accuracy in medical practice by those trained with virtual reality ABBOTT PARK, Ill., Dec. 9, 2020 — Abbott today announced the global release of its first virtual reality-based […]
– The EnSite™ X EP System is a new cardiac mapping system designed from electrophysiologist input to optimize cardiac ablation procedures – System offers electrophysiologists a new platform of options to provide consistent performance, regardless of the patient’s cardiac anatomy ABBOTT PARK, Ill., Nov. 2, 2020 — Abbott today announced it […]
— Considered as the industry’s equivalent of the Nobel Prize in biopharmaceutical and medical technology research, Prix Galien USA honored MitraClip as the Best Medical Technology for 2020 — The groundbreaking MitraClip therapy has positively impacted the lives of more than 100,000 people globally living with mitral regurgitation, or a […]
BILLERICA, Mass.–(BUSINESS WIRE)–Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced it has entered into a non-exclusive royalty-bearing license agreement with Abbott Laboratories (NYSE: ABT), the global healthcare company. The non-exclusive license grants Abbott access to Quanterix’ portfolio of bead-based technology […]
– CE Mark for MitraClip G4 offers physicians an innovative next-generation system with more options for mitral valve repair using proven clip-based technology – MitraClip is a first-of-its-kind transcatheter mitral valve therapy, now on its fourth generation, improving further on MitraClip’s history as a safe and effective treatment option ABBOTT […]
– The LIFE-BTK trial will evaluate the company’s new drug-eluting resorbable scaffold (DRS), known as the Esprit BTK System, for the treatment of blocked arteries below-the-knee (BTK) – Esprit BTK was granted breakthrough device designation by the U.S. FDA – There are no stents or drug-coated balloons currently approved for […]
– Recurrent irregular heartbeat–also known as atrial fibrillation–impacts more than 16 million people globally – Trial supports Abbott’s focus on being the best partner for electrophysiologists treating people living with atrial fibrillation ABBOTT PARK, Ill., Aug. 4, 2020 /PRNewswire/ — Abbott (NYSE: ABT) today announced first enrollments in the TactiFlex PAF IDE study to […]
